Contact us to get started

Hope begins here.

If you're an HR or benefits professional seeking cancer resources for your employees, or a consultant looking to provide best-in-class cancer support for your clients, share a few details below. We’ll reach out to help your company get started.

If you’re an employee looking for your AccessHope benefit, call 800.423.3232 and select Option 1.

January 27, 2021
JAMA Network Open

Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-vs-Host Disease—Another Hopeful Step Forward

AccessHope’s Vice President and Executive Clinical Director Joseph Alvarnas, MD, published a study in JAMA Network Open highlighting the use of a new treatment for the potentially life-ending chronic graft-vs-host disease (cGVHD) resulting from allogeneic hematopoietic stem cell transplantation (HSCT). The study progressively found that integrating evidence-based advances in the multidisciplinary care management of patients with cGVHD by a coordinated expert care team may lead to more-effective, personalized care solutions for this unique population.

Read Full Article Here